Format

Send to

Choose Destination
Therapie. 2018 Oct 28. pii: S0040-5957(18)30243-9. doi: 10.1016/j.therap.2018.09.074. [Epub ahead of print]

Interest and challenges of pharmacoepidemiology for the study of drugs used in diabetes.

Author information

1
Service de pharmacologie médicale, université de Bordeaux, UMR 1219, 33076 Bordeaux cedex, France; Service de pharmacologie médicale, pôle de santé publique, CHU de Bordeaux, 33000 Bordeaux, France. Electronic address: francesco.salvo@u-bordeaux.fr.
2
Department of medical pharmacology and toxicology, CHU Montpellier university hospital, 34090 Montpellier, France; Laboratory of biostatistics, epidemiology and public health (EA 2415), faculty of medicine, university of Montpellier, 34090 Montpellier, France.

Abstract

In the field of diabetes, pharmacoepidemiologic (PE) studies are numerous and represent an essential tool to assess the real life effects of diabetes drugs. However, the specificity of the study of drugs used in diabetes, characterized by a high frequency of switches, interruptions and add-on, must be kept in mind by pharmacoepidemiologists in order to perform well-conducted studies and avoid several biases. In this article, the authors discussed the specific interest of PE studies in the field of diabetes, provide a brief overview of biases that can affect those studies, and suggest pragmatic solutions for more correct results and appropriate interpretation.

KEYWORDS:

Database studies; Diabetes mellitus; Pharmacoepidemiology; Post-marketing surveillance; Real-world evidence

Supplemental Content

Loading ...
Support Center